Maintenance fees coming due
5 maintenance fees come due in the 12 months from Nov 17, 2026, the next on Dec 13, 2026. Unpaid by Jun 14, 2027, that one lapses early.
A maintenance fee does not end a patent on its due date. It falls due at 3.5, 7.5
and 11.5 years from grant, and the patent lapses only if the fee is still unpaid at the end of the
six month grace period that follows.
| Patent | Title | Holder | Status | Fee due | Lapses if unpaid | Expires | Confidence |
|---|---|---|---|---|---|---|---|
| US 11,673,953 | DLL3 Targeting Chimeric Antigen Receptors and Binding Agents In force Fee due Dec 13, 2026 Lapses if unpaid Jun 14, 2027 · High confidence | Allogene Therapeutics, Inc. | In force | Dec 13, 2026 | Jun 14, 2027 | High confidence | |
| US 11,732,041 | Antibodies Against 4G7-DERIVED Chimeric Antigen Receptors In force Fee due Feb 22, 2027 Lapses if unpaid Aug 23, 2027 · High confidence | Allogene Therapeutics, Inc. | In force | Feb 22, 2027 | Aug 23, 2027 | High confidence | |
| US 11,781,248 | Anti-Talen Antibodies and Uses Thereof In force Fee due Apr 10, 2027 Lapses if unpaid Oct 12, 2027 · High confidence | Allogene Therapeutics, Inc. | In force | Apr 10, 2027 | Oct 12, 2027 | High confidence | |
| US 11,786,553 | Chimeric Cytokine Receptors Bearing a PD-1 Ectodomain In force Fee due Apr 17, 2027 Lapses if unpaid Oct 18, 2027 · High confidence | Allogene Therapeutics, Inc. | In force | Apr 17, 2027 | Oct 18, 2027 | High confidence | |
| US 11,896,617 | Polynucleotides Encoding Rituximab-Resistant Chimeric Antigen Receptors In force Fee due Aug 13, 2027 Lapses if unpaid Feb 14, 2028 · High confidence | Allogene Therapeutics, Inc. | In force | Aug 13, 2027 | Feb 14, 2028 | High confidence |
5 of 5 patents shown. Soonest fee due date first, then patent number.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.